The Indian Council of Medical Research (ICMR) and Panacea Biotec have launched the first phase three clinical trial for an indigenous dengue vaccine, DengiAll. Conducted across 19 sites in 18 states, this trial aims to involve over 10,335 healthy adults. The vaccine, developed by Panacea Biotec, follows promising results from earlier trials and is a significant step in India's fight against dengue. With no licensed vaccine currently available in India, this initiative highlights the country’s progress in vaccine research and its commitment to improving public health.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.